Technical Analysis for FOLD - Amicus Therapeutics, Inc.

Grade Last Price % Change Price Change
grade A 16.85 -1.86% -0.32
FOLD closed down 1.86 percent on Monday, October 19, 2020, on 1.19 times normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
Earnings due: Nov 9
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical FOLD trend table...

Date Alert Name Type % Chg
Bearish Engulfing Bearish 0.00%
Jack-in-the-Box Bullish Bullish Swing Setup 0.00%
Upper Bollinger Band Walk Strength 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
New 52 Week Closing High Bullish -1.86%
Expansion Breakout Bullish Swing Setup -1.86%
Pocket Pivot Bullish Swing Setup -1.86%
Older End-of-Day Gignals for FOLD ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 2 % about 5 hours ago
60 Minute Opening Range Breakdown about 5 hours ago
Up 2% about 8 hours ago
Up 1% about 10 hours ago
Down 1% about 10 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs known as pharmacological chaperones. It develops pharmacological chaperones as next-generation medicines for a range of rare and orphan diseases with a focus on improved therapies for lysosomal storage disorders. The company's development programs include small molecules as monotherapy treatments for Fabry and other lysosomal storage diseases, and enzyme replacement therapy (ERT). Its chaperone-advanced replacement therapy programs comprise chaperones co-administered with currently marketed ERTs, as well as proprietary therapeutic enzymes co-formulated with pharmacological chaperones as next-generation ERTs. The company's primary product includes migalastat HCl, a product candidate for Fabry disease that is in Phase III global registration studies for patients with genetic mutations. Its products also comprise AT2220, which has completed Phase II safety used for the treatment of Pompe disease; and AT3375 and afegostat tartrate that are in preclinical studies used for treating Gaucher disease. The company has strategic collaboration with GlaxoSmithKline PLC to develop and commercialize migalastat HCl. Amicus Therapeutics, Inc. was founded in 2002 and is based in Cranbury, New Jersey.
Medicine Biopharmaceutical Rare Diseases Inborn Errors Of Metabolism Lipid Storage Disorders Enzyme Replacement Therapy Orphan Drugs Fabry Disease Gaucher Disease Lysosomal Storage Disorders Pompe Disease Protein Folding Rare And Orphan Diseases

Is FOLD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 17.67
52 Week Low 6.25
Average Volume 1,823,688
200-Day Moving Average 12.36
50-Day Moving Average 14.49
20-Day Moving Average 14.87
10-Day Moving Average 15.87
Average True Range 0.70
ADX 22.89
+DI 31.02
-DI 13.19
Chandelier Exit (Long, 3 ATRs ) 15.56
Chandelier Exit (Short, 3 ATRs ) 14.89
Upper Bollinger Band 17.32
Lower Bollinger Band 12.42
Percent B (%b) 0.9
BandWidth 32.94
MACD Line 0.73
MACD Signal Line 0.43
MACD Histogram 0.3024
Fundamentals Value
Market Cap 4.36 Billion
Num Shares 259 Million
EPS -2.13
Price-to-Earnings (P/E) Ratio -7.91
Price-to-Sales 17.07
Price-to-Book 10.84
PEG Ratio -0.18
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.99
Resistance 3 (R3) 18.09 17.80 17.80
Resistance 2 (R2) 17.80 17.51 17.76 17.74
Resistance 1 (R1) 17.33 17.33 17.19 17.23 17.67
Pivot Point 17.04 17.04 16.97 17.00 17.04
Support 1 (S1) 16.57 16.75 16.43 16.47 16.03
Support 2 (S2) 16.28 16.57 16.24 15.96
Support 3 (S3) 15.81 16.28 15.90
Support 4 (S4) 15.71